Annalise.ai Nets FDA Clearance for Triage Solution Via Breakthrough Devices Designation
Annalise.ai has received 510(k) clearance from the US Food and Drug Administration (FDA) for the triage and notification of obstructive hydrocephalus (OHCP) on non-contrast brain CT scans. The company has also received FDA Breakthrough Device Designation for its obstructive hydrocephalus software tool. Annalise.ai says this is the first radiology triage device to be granted Breakthrough status since the inception of the FDA Breakthrough Devices Program.
The FDA's Breakthrough Devices Program identifies medical devices that improve the
treatment or diagnosis of life-threatening or debilitating conditions. It aims to grant quick
access to these devices to healthcare providers. To be authorized for marketing, these
devices must meet the FDA's strict safety and effectiveness standards.
Annalise.ai’s solution enables both passive and active notifications for suspected OHCP cases identified on unenhanced head CT scans. The newly cleared algorithm bolsters Annalise.ai's US portfolio to a total of ten FDA-cleared findings– five for chest X-rays (CXR) and five for head CT scans (CTB).
Lakshmi Gudapakkam, CEO of Annalise.ai, stated, "Our FDA clearances, including this latest addition, underscore our dedication to revolutionizing medical imaging. Annalise.ai is proud to offer a comprehensive suite of AI solutions that significantly enhance diagnostic capabilities and assist in delivering prompt, life-saving interventions for conditions like obstructive hydrocephalus.”
Dr Rick Abramson, Chief Medical Officer at Annalise.ai, added, “Our advanced algorithms support radiologists by facilitating prioritization of non-contrast head CT studies with suspected critical findings, thereby optimizing radiology workflow. With its set of clearances, Annalise.ai promotes faster report turnaround times by identifying and elevating critical cases for immediate attention.”
Obstructive hydrocephalus, a potentially life-threatening condition, involves the accumulation of cerebrospinal fluid in the cranial vault, leading to elevated intracranial pressure that can escalate rapidly if left untreated. The Breakthrough Device Designation from the FDA highlights Annalise.ai's commitment to expediting patient access to advanced medical solutions that address critical healthcare needs.